Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GenAssist Therapeutics

Request full access

Develops gene therapy drugs using base editing technology

Suzhou Shi, ChinaFounded 2020Biotech & Life Sciences

About GenAssist Therapeutics

GenAssist Therapeutics, established in Suzhou, China, in July 2020, is a clinical-stage biotechnology firm focused on developing gene-editing therapies for genetic diseases. The company was co-founded by Dr. Chunyan He (CEO) and Dr. Xing Chang (Chief Scientific Advisor). Dr. He brings extensive experience in viral product development and business incubation, while Dr. Chang is a scientist from Westlake University recognized as a pioneer in the research and application of base editing technology in China, particularly for muscle-related diseases.

The company's core technology is a proprietary base editing platform known as Targeted AID-based Mutagenesis (TAM), for which it holds global rights. This technology aims to precisely repair disease-causing gene mutations in situ, offering the potential for a permanent cure. GenAssist's primary business involves the research and development of these novel gene-editing drugs, with a business model centered on advancing its product pipeline through clinical trials and eventual commercialization. The company operates through its main entity in Suzhou and has subsidiaries in Shanghai and Boston, USA.

The lead product candidate, GEN6050X, is a base editing drug developed to treat Duchenne Muscular Dystrophy (DMD), a rare genetic disorder that causes progressive muscle degeneration and weakness. DMD affects approximately one in every 3,500-5,000 newborn boys and currently lacks effective treatments. GEN6050X is designed for patients amenable to exon 50 skipping and is administered intravenously via a dual AAV9 vector system. The goal is to permanently restore the production of the essential dystrophin protein with a single treatment. In March 2025, GenAssist received Investigational New Drug (IND) clearance from the U.S. FDA for GEN6050X, marking it as a significant milestone for a gene editing therapy for DMD. An investigator-initiated trial for GEN6050X began in September 2024, with the first patient being dosed.

Since its inception, GenAssist has secured significant funding to advance its research. A pre-Series A round in July 2021 was led by Sequoia Capital China Fund, and a Series A round in December 2022 was led by the AstraZeneca-CICC Healthcare Industry Fund, with participation from Baidu Ventures and others. These funds are allocated to advancing preclinical studies, IND applications, and clinical trials for its therapeutic pipeline.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
25.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2022 $20M $80M AZ-CICC Healthcare Investment Fund ↗
SEEDEquity / VC Dec 2020 $0 — Redhill Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

GenAssist Therapeutics website traffic

Latest recorded traffic for GenAssist Therapeutics is 1.4K monthly website visits, down 6.7% over the last three months. GenAssist Therapeutics's team grew 0% over the past year.

Latest monthly visits1.4K 3-month web change-6.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

GenAssist Therapeutics in the Suzhou Shi ecosystem

Live from Dealroom

The GenAssist Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Redhill Capital

Series A1 investor entered at this stage

  • AZ-CICC Healthcare Investment Fund

Other known investors2 additional known investors

  • Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences
  • Westlake University
Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GenAssist Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GenAssist Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.